<DOC>
	<DOCNO>NCT02084654</DOCNO>
	<brief_summary>Exenatide , GLP-1 agonist approve lower blood glucose concentration patient type 2 diabetes , associate restoration first-phase insulin response administer intravenously patient type 2 diabetes . In long clinical trial , associate progressive decrease body weight , improvement dyslipidemia characterize insulin resistance , although insulin resistance quantify . The investigator seek determine whether exenatide would similar effect individual diabetic . particular , drug effect beta cell function insulin sensitivity would subject less confounding change blood glucose prediabetic population , allow clear evaluation physiological effect drug metabolic endpoint . The investigator compare 2 group prediabetic insulin resistant individual , weight loss diet one group exenatide placebo . The investigator evaluate restoration first phase insulin response , potential glucose lower effect , include reversal prediabetes hypoglycemia , improvement insulin resistance .</brief_summary>
	<brief_title>Exenatide Weight Loss Diabetes Prevention</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Healthy Men woman , BMI 2737kgm2 , Fasting plasma glucose = &gt; 100 mg/dL = &lt; 99 125m g/dl 2 hour post OGTT = &gt; 140 mg/dl = &lt; 199 mg/dl Diabetes , Active cardiac , kidney , liver , pulmonary , major organ disease cause exclusion . Other exclusionary criterion include : use corticosteroid , diet medication , antipsychotic medication , history eat disorder , history bariatric surgery , active malignancy , recent weight change 2 % , inability attend followup visit , excessive alcohol use , investigator 's discretion patient 's best interest</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>prediabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>weight loss</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>acute insulin response</keyword>
	<keyword>insulin secretion</keyword>
</DOC>